Bortezomib in relapsed or refractory myeloma patients

被引：0
|
作者：
Leonetti Crescenzi, S. [1 ]
Piccioni, A. L. [1 ]
Bagnato, A. [1 ]
机构：
[1] Osped Sandro Pertini, UOC Ematol, ASL Roma B, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [21] Bendamustine and prednisone in combination with Bortezomib in the treatment of patients with relapsed/refractory multiple myeloma
    Poenisch, W.
    Bourgeois, M.
    Heyn, S.
    Wagner, I
    Jaekel, N.
    Rohrberg, R.
    Hurtz, H. -J.
    Schmalfeld, M.
    Assmann, M.
    Edelmann, T.
    Mohren, M.
    Hoffmann, F. A.
    Schwarzer, A.
    Hensel, G.
    Loeschke, K.
    Becker, C.
    Krahl, R.
    Al-Ali, H. K.
    Niederwieser, D.
    ONKOLOGIE, 2012, 35 : 144 - 144
  • [22] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Moll, Barbara
    Heyn, Simone
    Jaekel, Nadja
    Wagner, Ina
    Rohrberg, Robert
    Hurtz, Hans-Juergen
    Schmalfeld, Marion
    Assmann, Michael
    Edelmann, Thomas
    Mohren, Martin
    Hoffmann, Franz Albert
    Becker, Cornelia
    Schwarzer, Andreas
    Schoenfelder, Uta
    Zehrfeld, Thomas
    Hensel, Gerald
    Loeschcke, Kerstin
    Krahl, Rainer
    Al Ali, Haifa
    Niederwieser, Dietger
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 499 - 508
  • [23] Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
    Wolfram Pönisch
    Malvina Bourgeois
    Barbara Moll
    Simone Heyn
    Nadja Jäkel
    Ina Wagner
    Robert Rohrberg
    Hans-Jürgen Hurtz
    Marion Schmalfeld
    Michael Aßmann
    Thomas Edelmann
    Martin Mohren
    Franz Albert Hoffmann
    Cornelia Becker
    Andreas Schwarzer
    Uta Schönfelder
    Thomas Zehrfeld
    Gerald Hensel
    Kerstin Löschcke
    Rainer Krahl
    Haifa Al Ali
    Dietger Niederwieser
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 499 - 508
  • [24] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    S K Kumar
    B LaPlant
    V Roy
    C B Reeder
    M Q Lacy
    M A Gertz
    K Laumann
    M A Thompson
    T E Witzig
    F K Buadi
    C E Rivera
    J R Mikhael
    P L Bergsagel
    P Kapoor
    L Hwa
    R Fonseca
    A K Stewart
    A Chanan-Khan
    S V Rajkumar
    A Dispenzieri
    Blood Cancer Journal, 2015, 5 : e338 - e338
  • [25] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [26] Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma
    Castelli, Roberto
    Pantaleo, Giuseppe
    Gallipoli, Paolo
    Gidaro, Antonio
    Arquati, Massimo
    Wu, Maddalena A.
    Deliliers, Giorgio Lambertenghi
    ANTI-CANCER DRUGS, 2015, 26 (10) : 1078 - 1082
  • [27] Bortezomib in combination with bendamustine and preduisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Wang, Song-Yau
    Heyn, Simone F.
    Jaekel, Nadja
    Braunert, Leanthe
    Rohrberg, Robert
    Hurtz, Hans Juergen
    Hoffmann, Franz Albert
    Schwarzer, Andreas
    Becker, Cornelia
    Al Ali, Haifa
    Niederwieser, Dietger W.
    BLOOD, 2007, 110 (11) : 799A - 800A
  • [28] BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS IN A COHORT OF 52 PATIENTS
    Canovas, A.
    Alonso, J. J.
    Barreiro, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 617 - 618
  • [29] Economic evaluation of bortezomib in the treatment of relapsed and refractory multiple myeloma patients in Canada
    Yoong, K
    Bagust, A
    Haycox, AR
    Mujica-Mota, R
    Dhawan, R
    VALUE IN HEALTH, 2005, 8 (06) : A36 - A36
  • [30] Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
    Richardson, PGG
    Barlogie, B
    Berenson, J
    Singhal, S
    Jagannath, S
    Irwin, D
    Rajkumar, SV
    Hideshima, T
    Xiao, H
    Esseltine, D
    Schenkein, D
    Anderson, KC
    BLOOD, 2005, 106 (09) : 2977 - 2981
12345